Kyprolis

Carfilzomib, the active ingredient in Kyprolis, is a proteasome inhibitor presented as a 20 mg/mL injectable solution for intravenous use. It treats multiple myeloma in patients with relapsed or refractory disease and is indicated for adult patients who have received prior therapy.

GNH USA supplies Kyprolis as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The product is manufactured under EU GMP standards and distributed for clinical use.

Kyprolis (carfilzomib) is used in the treatment of hematologic malignancies, specifically targeting proteasome activity in multiple myeloma. Multiple myeloma (relapsed or refractory): improves progression‑free survival and overall response rates in patients who have received at least one prior therapy.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Nausea: mild to moderate gastrointestinal upset. - Anemia: reduced red blood cell count causing weakness. - Thrombocytopenia: lowered platelet levels increasing bleeding risk. - Hypertension: elevated blood pressure during treatment. - Dyspnea: shortness of breath experienced by some patients.

Serious or Rare Side Effects: - Cardiac failure: reduced heart function requiring monitoring. - Pulmonary embolism: blood clot in the lungs, a medical emergency. - Severe infusion reactions: anaphylaxis‑like symptoms during administration. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Severe dyspnea: acute respiratory distress needing immediate care.

Kyprolis requires careful monitoring due to its potent antineoplastic activity. - Cardiac monitoring: assess baseline function and watch for signs of heart failure. - Blood pressure control: measure regularly and manage hypertension promptly. - Hematologic surveillance: monitor complete blood counts for anemia, thrombocytopenia, and neutropenia. - Pulmonary assessment: evaluate for respiratory symptoms and intervene early. - Hypersensitivity avoidance: discontinue if severe infusion reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kyprolis may interact with several concomitant medications. Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase carfilzomib exposure and toxicity. - Other proteasome inhibitors: additive toxicity risk, avoid concurrent use. - QT‑prolonging agents: heightened risk of cardiac arrhythmias. Moderate Interactions (Monitor Closely): - Anticoagulants: increased bleeding risk due to thrombocytopenia. - Antihypertensives: possible additive blood pressure effects. - CYP3A4 inducers: may reduce carfilzomib efficacy, require dose adjustment.